![](https://pmlive.com/wp-content/uploads/2024/02/NEW_AstraZeneca_shutterstock_1820522576-640.jpg)
AstraZeneca signs exclusive licensing deal worth over $500m for Pinetree’s EGFR degrader
AstraZeneca (AZ) and Pinetree Therapeutics have entered into an exclusive option and global licence agreement worth more than $500m for a preclinical epidermal growth factor receptor (EGFR) degrader. The deal gives AZ an exclusive option to licence …